文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

在痘病毒和蛋白加强之前,用一种有效的 HIV-1 DNA 疫苗进行预刺激会影响免疫反应的质量。

Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.

机构信息

Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.

Biodesign Institute, Arizona State University, Tempe, Arizona, USA.

出版信息

J Virol. 2019 Jan 17;93(3). doi: 10.1128/JVI.01529-18. Print 2019 Feb 1.


DOI:10.1128/JVI.01529-18
PMID:30429343
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6340047/
Abstract

The use of heterologous immunization regimens and improved vector systems has led to increases in immunogenicity of HIV-1 vaccine candidates in nonhuman primates. In order to resolve interrelations between different delivery modalities, three different poxvirus boost regimens were compared. Three groups of rhesus macaques were each primed with the same DNA vaccine encoding Gag, Pol, Nef, and gp140. The groups were then boosted with either the vaccinia virus strain NYVAC or a variant with improved replication competence in human cells, termed NYVAC-KC. The latter was administered either by scarification or intramuscularly. Finally, macaques were boosted with adjuvanted gp120 protein to enhance humoral responses. The regimen elicited very potent CD4 and CD8 T cell responses in a well-balanced manner, peaking 2 weeks after the boost. T cells were broadly reactive and polyfunctional. All animals exhibited antigen-specific humoral responses already after the poxvirus boost, which further increased following protein administration. Polyclonal reactivity of IgG antibodies was highest against HIV-1 clade C Env proteins, with considerable cross-reactivity to other clades. Substantial effector functional activities (antibody-dependent cell-mediated cytotoxicity and antibody-dependent cell-mediated virus inhibition) were observed in serum obtained after the last protein boost. Notably, major differences between the groups were absent, indicating that the potent priming induced by the DNA vaccine initially framed the immune responses in such a way that the subsequent boosts with NYVAC and protein led only to an increase in the response magnitudes without skewing the quality. This study highlights the importance of selecting the best combination of vector systems in heterologous prime-boost vaccination regimens. The evaluation of HIV vaccine efficacy trials indicates that protection would most likely correlate with a polyfunctional immune response involving several effector functions from all arms of the immune system. Heterologous prime-boost regimens have been shown to elicit vigorous T cell and antibody responses in nonhuman primates that, however, qualitatively and quantitatively differ depending on the respective vector systems used. The present study evaluated a DNA prime and poxvirus and protein boost regimen and compared how two poxvirus vectors with various degrees of replication capacity and two different delivery modalities-conventional intramuscular delivery and percutaneous delivery by scarification-impact several immune effectors. It was found that despite the different poxvirus boosts, the overall immune responses in the three groups were similar, suggesting the potent DNA priming as the major determining factor of immune responses. These findings emphasize the importance of selecting optimal priming agents in heterologous prime-boost vaccination settings.

摘要

使用异源免疫方案和改良的载体系统已导致 HIV-1 疫苗候选物在非人类灵长类动物中的免疫原性增加。为了解决不同传递方式之间的相互关系,比较了三种不同的痘苗病毒增强方案。三组恒河猴均用相同的 DNA 疫苗进行初次免疫,该疫苗编码 Gag、Pol、Nef 和 gp140。然后,将三组恒河猴用牛痘病毒株 NYVAC 或在人细胞中复制能力增强的变体 NYVAC-KC 进行增强。后者通过划痕或肌肉内给药。最后,用佐剂 gp120 蛋白增强灵长类动物的体液反应。该方案在增强后 2 周内引发了非常有效的 CD4 和 CD8 T 细胞反应,平衡良好。T 细胞反应广泛且多功能。所有动物在痘苗病毒增强后已经表现出抗原特异性体液反应,在给予蛋白后进一步增加。多克隆 IgG 抗体反应性最高针对 HIV-1 谱系 C Env 蛋白,对其他谱系有相当大的交叉反应性。在最后一次蛋白增强后获得的血清中观察到大量效应功能活性(抗体依赖性细胞介导的细胞毒性和抗体依赖性细胞介导的病毒抑制)。值得注意的是,各组之间没有明显差异,表明 DNA 疫苗诱导的强烈初始免疫以这种方式构成了免疫反应,使得随后用 NYVAC 和蛋白进行的增强仅增加了反应幅度,而没有改变质量。这项研究强调了在异源初免-加强免疫接种方案中选择最佳载体系统组合的重要性。对 HIV 疫苗功效试验的评估表明,保护很可能与涉及免疫系统所有分支的几种效应功能的多功能免疫反应相关。异源初免-加强方案已在非人类灵长类动物中引发强烈的 T 细胞和抗体反应,但根据使用的不同载体系统,其质量和数量存在差异。本研究评估了 DNA 初免和痘苗病毒和蛋白加强方案,并比较了两种具有不同复制能力的痘苗病毒载体和两种不同的传递方式(常规肌肉内传递和划痕的经皮传递)如何影响几种免疫效应物。结果发现,尽管有不同的痘苗增强,但三组的总体免疫反应相似,表明强大的 DNA 初免是免疫反应的主要决定因素。这些发现强调了在异源初免-加强疫苗接种方案中选择最佳初免剂的重要性。

相似文献

[1]
Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.

J Virol. 2019-1-17

[2]
HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.

J Virol. 2017-4-13

[3]
Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.

J Virol. 2016-3-28

[4]
Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.

J Virol. 2019-1-17

[5]
Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.

J Virol. 2015-8

[6]
HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.

J Virol. 2017-11-30

[7]
Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.

J Virol. 2017-4-13

[8]
Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.

PLoS One. 2015-4-9

[9]
Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study.

Front Immunol. 2022

[10]
Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.

J Virol. 2019-9-30

引用本文的文献

[1]
Development of a Two-Component Nanoparticle Vaccine Displaying an HIV-1 Envelope Glycoprotein that Elicits Tier 2 Neutralising Antibodies.

Vaccines (Basel). 2024-9-18

[2]
Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env protein.

Front Immunol. 2023

[3]
Rendezvous with Vaccinia Virus in the Post-smallpox Era: R&D Advances.

Viruses. 2023-8-15

[4]
An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralising Antibodies against HIV-1 and HIV-2 Isolates.

Int J Mol Sci. 2023-5-22

[5]
Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants.

Front Immunol. 2023

[6]
Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study.

Front Immunol. 2022

[7]
Design and Immunological Validation of Papillomavirus Type 3 Based Vaccine Candidates in Outbred Mice: Basis for Future Testing of a Therapeutic Papillomavirus Vaccine in NHPs.

Front Immunol. 2021

[8]
Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge.

Front Immunol. 2020

[9]
COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.

J Virol. 2021-3-10

[10]
A Zigzag but Upward Way to Develop an HIV-1 Vaccine.

Vaccines (Basel). 2020-9-8

本文引用的文献

[1]
Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.

J Virol. 2019-1-17

[2]
Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches.

Immunity. 2017-6-20

[3]
Early antibody therapy can induce long-lasting immunity to SHIV.

Nature. 2017-3-23

[4]
Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.

J Infect Dis. 2017-5-1

[5]
HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.

J Virol. 2017-4-13

[6]
Complex immune correlates of protection in HIV-1 vaccine efficacy trials.

Immunol Rev. 2017-1

[7]
The quest for an antibody-based HIV vaccine.

Immunol Rev. 2017-1

[8]
Patterns of HIV/SIV Prevention and Control by Passive Antibody Immunization.

Front Microbiol. 2016-11-2

[9]
Pox-Protein Public Private Partnership program and upcoming HIV vaccine efficacy trials.

Curr Opin HIV AIDS. 2016-11

[10]
Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa.

PLoS One. 2016-7-21

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索